--- title: "Pre-market hot trades in US stocks: Dollar General up 7.49% pre-market; Moderna down 3.46% pre-market" type: "News" locale: "en" url: "https://longbridge.com/en/news/297171372.md" description: "Dollar General pre-market up 7.49%; Moderna pre-market down 3.46%; Volitionrx pre-market up 83.99%; Mercer International pre-market up 58.35%; Meituan Technology pre-market up 47.71%" datetime: "2026-08-27T10:52:50.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/297171372.md) - [en](https://longbridge.com/en/news/297171372.md) - [zh-HK](https://longbridge.com/zh-HK/news/297171372.md) generator: "portal-rs" --- # Pre-market hot trades in US stocks: Dollar General up 7.49% pre-market; Moderna down 3.46% pre-market **Pre-market Hot Trades in US Stocks** Dollar General is up 7.49% in pre-market trading. Based on recent key news: 1. On August 26, Dollar General is set to release its second-quarter earnings report, with the market expecting an adjusted earnings per share of $2.01 and sales of $11.2 billion. Despite a nearly 7% decline in stock price year-to-date, investor optimism regarding its earnings performance has driven the stock price up. Source: WSJ 2. On August 26, analyst Rupesh Parikh maintained a buy rating on Dollar General and set a target price of $150. The analyst's positive rating and target price have boosted market confidence, propelling the stock price higher. Source: Oppenheimer 3. On August 26, Dollar General's store visit numbers have surpassed those of Dollar Tree for most of this year. Despite rising oil prices, increased consumer demand for essentials has supported Dollar General's sales growth. Source: Placer.ai The consumer goods industry is significantly affected by inflation and oil prices. Moderna is down 3.46% in pre-market trading. Based on recent key news: 1. On August 26, the mRNA cancer vaccine jointly developed by Moderna and MSD reached a key endpoint in Phase III clinical trials, but the high price of nearly $500,000 per dose has sparked controversy, leading to a drop in stock price. Deutsche Bank raised its target price to $125. Source: Zhitong Finance 2. On August 24, Moderna's mRNA cancer vaccine achieved positive results for the first time in Phase III clinical trials, marking a shift in the paradigm of tumor treatment and driving the stock price up. Source: Huafu Securities 3. On August 25, Barclays raised Moderna's target price to $125, and the stock price rose by 8.4%. Source: Barclays The mRNA vaccine market has huge potential, and the industry outlook is optimistic. **Top Gainers in Pre-market US Stocks** VolitionRx is up 83.99% in pre-market trading. Based on recent key news: 1. On August 26, VolitionRx transitioned its Nu.Q NETs testing to the Sysmex platform and began discussions for broader commercial agreements. This move enhances the prospects for deploying sepsis-focused testing on Sysmex analyzers, strengthening licensing prospects with major diagnostic groups. 2. On August 26, VolitionRx announced a 112% increase in revenue for the first half of the year and achieved a significant milestone of $5 million in the veterinary field. This achievement is attributed to recent collaboration announcements and ongoing licensing discussions with twelve globally recognized diagnostic companies. 3. On August 26, VolitionRx's latest announcement mentioned that it is actively engaged in licensing discussions with over a dozen global diagnostic and liquid biopsy companies, further solidifying its market position. Industry collaboration and revenue growth are significant, and the market response is positive Mercer International pre-market rose 58.35%. Based on recent key news: 4. On August 26, the Canadian government announced a financial aid of CAD 20 million (approximately USD 14 million) to Mercer International's subsidiary, Mercer Peace River Pulp Ltd. This funding will be used for modernization, productivity enhancement, as well as bioenergy expansion and carbon capture projects. Following this announcement, Mercer International's stock price surged. 5. On August 26, Mercer International announced its significant position in the North American and European forest products markets. The company's annual production capacity includes 2.1 million tons of pulp, 1,023 million board feet of lumber, 210,000 cubic meters of cross-laminated timber, 45,000 cubic meters of glued wood, 17 million pallets, and 230,000 tons of biofuels. This news boosted investor confidence in the company's future growth, driving the stock price up. 6. On August 26, technical sentiment signals indicated a sell, but the market reacted strongly to Mercer International's positive news, leading to a counter-trend rise in stock price. The recent industry performance has been strong, with clear policy support. Meitu Technology pre-market rose 47.71%. Based on recent key news: 1. On August 26, Meitu Technology Co., Ltd. released its latest announcement through the EDGAR system of the U.S. Securities and Exchange Commission, disclosing the company's recent financial status and business developments. This announcement triggered a positive market reaction, significantly boosting the stock price. 2. On August 25, Liberty Broadband reported a net loss of USD 3.2 billion by the end of 2025, raising market concerns about its prospects. In contrast, Meitu Technology's financial situation is relatively stable, attracting more investor attention. 3. Recently, the market has favored companies with actual cash flow and clear infrastructure advantages, and Meitu Technology is one of them, further driving its stock price up. The market is more inclined towards companies with stable cash flow and infrastructure advantages ### Related Stocks - [DG.US](https://longbridge.com/en/quote/DG.US.md) - [MRNA.US](https://longbridge.com/en/quote/MRNA.US.md) - [VNRX.US](https://longbridge.com/en/quote/VNRX.US.md) - [MERC.US](https://longbridge.com/en/quote/MERC.US.md) - [WNW.US](https://longbridge.com/en/quote/WNW.US.md) ## Related News & Research - [Dollar General partners with RELEX Solutions for forecasting and replenishment platform](https://longbridge.com/en/news/297182543.md) - [Wolfe Research Just Upgraded Moderna Stock. Here's Why.](https://longbridge.com/en/news/296951590.md) - [Moderna stock soars on cancer vaccine success](https://longbridge.com/en/news/296405393.md) - [Dollar General's Q2 sales slightly beat estimates; raises FY forecast](https://longbridge.com/en/news/297172502.md) - [If You Invested $1,000 In Moderna Stock at IPO, Here's How Much You'd Have Now](https://longbridge.com/en/news/296641626.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**